Print | Email | Share | Comments (1)

Experimental Heart Drug Shows Unexpected Benefit In Preventing Onset of Diabetes

Jun 19, 2008

Unexpected results... succinobucol seemed to have no effect on test subjects but one of the drug's side effects caught scientists' eyes. They discovered that it reduced the odds of developing diabetes by 64 percent.

Canadian researchers report that succinobucol, an anti-oxidant drug used to treat cardiovascular inflammation, appears to have a beneficial effect in lowering the risk of developing diabetes. Even patients who already have diabetes, they say, achieve better blood sugar control while on the drug.

Researchers tested the drug over two years on 6,144 people, of whom 37 percent had diabetes. All of the test subjects either had been hospitalized for heart attack or unstable angina, a dangerous heart rhythm condition. Although half of the participants received succinobucol and the other half a placebo, all of them were taking other heart-related drugs, such as beta blockers, ACE inhibitors and statins.

Unexpected Results

One of the drug’s unexpected side effects caught scientists’ eyes. While succinobucol itself seemed to have no effect on test subjects—those taking and those not taking the drug had the same incidences of heart attack, stroke or other cardiovascular events—they discovered that it reduced the odds of developing diabetes by 64 percent.

Among the non-diabetes participants at the start of the study, 4.2 percent of those not taking succinobucol later developed the disease, compared to 1.64 percent of those taking the drug. Researchers also noted that people with diabetes who entered the study achieved better blood sugar control if they took succinobucol than people with diabetes who didn’t take the drug.

The study’s author, Dr. Jean-Claude Tardif, director of the research center at the Montreal Heart Institute in Canada, said that while succinobucol did not achieve its goal of reducing the risk of heart attack and stroke, its effect on reducing new cases of diabetes and helping glycemic control opens the drug up to new therapeutic possibilities.

Succinobucol is a chemical relative of probucol, a cholesterol-lowering drug that was taken off the market in the United States in 1995 because of side effects.

Source: The Lancet

Categories: Blood Sugar, Complementary Therapies, Diabetes, Diabetes, Heart Care & Heart Disease, Medications, Research, Type 1 Issues

Comments

Posted by Anonymous on 20 June 2008

The anti- inflammatroty drugs could have lipolytic and anti SAA protein activity; as result of this there may be delay in onset of diabetes

Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Registered User Anonymous

Your Name:	Your Email:	X

Recipient's Name:	Recipient's Email:

Your Chosen Username:	Your Email Address:

Chosen Password:	Confirm Password:

Email to a Friend

Experimental Heart Drug Shows Unexpected Benefit In Preventing Onset of Diabetes

You May Also Be Interested In...

Comments

Register...

Have Your Say...

Diabetes Health

Topics

Topics

Topics

Diabetes Health Medical Disclaimer

Comment: